Cargando…

Eculizumab in the Treatment of Acetylcysteine-Induced Atypical Hemolytic Uremic Syndrome

N-acetylcysteine overdose is almost exclusively an iatrogenic event. This rare complication can lead to hemolysis or atypical hemolytic uremic syndrome. A 53-year-old Caucasian male accidentally received a two-fold N-acetylcysteine overdose that resulted in a presentation compatible with the atypica...

Descripción completa

Detalles Bibliográficos
Autores principales: Jalbert, Arielle, Yao, Han, Fagnan, Mylène, Crevier, Benoît
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202342/
https://www.ncbi.nlm.nih.gov/pubmed/37223175
http://dx.doi.org/10.7759/cureus.37784
_version_ 1785045422381727744
author Jalbert, Arielle
Yao, Han
Fagnan, Mylène
Crevier, Benoît
author_facet Jalbert, Arielle
Yao, Han
Fagnan, Mylène
Crevier, Benoît
author_sort Jalbert, Arielle
collection PubMed
description N-acetylcysteine overdose is almost exclusively an iatrogenic event. This rare complication can lead to hemolysis or atypical hemolytic uremic syndrome. A 53-year-old Caucasian male accidentally received a two-fold N-acetylcysteine overdose that resulted in a presentation compatible with the atypical hemolytic uremic syndrome. The patient required temporary hemodialysis sessions, and he received treatment with eculizumab. This case report is the first reported N-acetylcysteine-induced atypical hemolytic uremic syndrome successfully treated with eculizumab. Clinicians should be aware of N-acetylcysteine overdose and its possible hemolytic complications.
format Online
Article
Text
id pubmed-10202342
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-102023422023-05-23 Eculizumab in the Treatment of Acetylcysteine-Induced Atypical Hemolytic Uremic Syndrome Jalbert, Arielle Yao, Han Fagnan, Mylène Crevier, Benoît Cureus Emergency Medicine N-acetylcysteine overdose is almost exclusively an iatrogenic event. This rare complication can lead to hemolysis or atypical hemolytic uremic syndrome. A 53-year-old Caucasian male accidentally received a two-fold N-acetylcysteine overdose that resulted in a presentation compatible with the atypical hemolytic uremic syndrome. The patient required temporary hemodialysis sessions, and he received treatment with eculizumab. This case report is the first reported N-acetylcysteine-induced atypical hemolytic uremic syndrome successfully treated with eculizumab. Clinicians should be aware of N-acetylcysteine overdose and its possible hemolytic complications. Cureus 2023-04-18 /pmc/articles/PMC10202342/ /pubmed/37223175 http://dx.doi.org/10.7759/cureus.37784 Text en Copyright © 2023, Jalbert et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Emergency Medicine
Jalbert, Arielle
Yao, Han
Fagnan, Mylène
Crevier, Benoît
Eculizumab in the Treatment of Acetylcysteine-Induced Atypical Hemolytic Uremic Syndrome
title Eculizumab in the Treatment of Acetylcysteine-Induced Atypical Hemolytic Uremic Syndrome
title_full Eculizumab in the Treatment of Acetylcysteine-Induced Atypical Hemolytic Uremic Syndrome
title_fullStr Eculizumab in the Treatment of Acetylcysteine-Induced Atypical Hemolytic Uremic Syndrome
title_full_unstemmed Eculizumab in the Treatment of Acetylcysteine-Induced Atypical Hemolytic Uremic Syndrome
title_short Eculizumab in the Treatment of Acetylcysteine-Induced Atypical Hemolytic Uremic Syndrome
title_sort eculizumab in the treatment of acetylcysteine-induced atypical hemolytic uremic syndrome
topic Emergency Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202342/
https://www.ncbi.nlm.nih.gov/pubmed/37223175
http://dx.doi.org/10.7759/cureus.37784
work_keys_str_mv AT jalbertarielle eculizumabinthetreatmentofacetylcysteineinducedatypicalhemolyticuremicsyndrome
AT yaohan eculizumabinthetreatmentofacetylcysteineinducedatypicalhemolyticuremicsyndrome
AT fagnanmylene eculizumabinthetreatmentofacetylcysteineinducedatypicalhemolyticuremicsyndrome
AT crevierbenoit eculizumabinthetreatmentofacetylcysteineinducedatypicalhemolyticuremicsyndrome